



Centre for
Public Health

Merseyside Inter Agency Drug Misuse Database

January - March 2010

**Liverpool Addiction and Offender Health
Team**

Quarter 4 2009/10

**Lloyd Baron, Steven Griffith,
Martin Chandler, Jim McVeigh**

DRAFT REPORT

The final version will be available on the IAD website

www.cph.org.uk/iad

Acknowledgements:

The Authors would like to thank the following for their valuable contributions to the production of this report: Ellie McCoy and Paul Duffy.

We would also like to thank the data providers for their efforts in assisting and maintaining the monitoring process.

Contacts:

Martin Chandler
IAD Manager
Centre for Public Health
Faculty of Health & Applied Social Sciences
Liverpool John Moores University
4th Floor, Kingsway House
Hatton Gardens
Liverpool
L3 2AY

(0151) 904 6031

m.chandler@ljmu.ac.uk

Lloyd Baron
IAD Researcher

(0151) 231 8014

L.R.Baron@ljmu.ac.uk

www.cph.org.uk/iad

Contents

	<u>Page</u>
Introduction	1
Arrest Referral	3
Table 1: Individuals assessed, by Gender and Age Group	
Table 2: Year to Date, by Gender and Age Group	
Table 3: Reported Main Drug(s) of Use, by Frequency of Use	
Needle and Syringe Programmes (NSPs)	5
Agency	
Table 4: Individuals by Gender	
Table 5: Individuals by Gender: Steroid Users omitted	
Table 6: Individuals by Age Group	
Table 7: Individuals by Age Group: Steroid Users omitted	
Table 8: Gender by Age Group of Individuals	
Table 9: Gender by Age Group: Steroid Users omitted	
Table 10: Year to Date, by Gender & Age Group	
Table 11: Year to Date, by Gender & Age Group: Steroid Users omitted	
Table 12: Main Drug of Use for New Agency NSP Clients, by Gender	
Table 13: Main Drug of Use for All Agency NSP Clients, by Gender	
Table 14: Main Drug of Use, for New Agency NSP Clients, by Age Group	
Pharmacy	11
Table 15: Individuals by Gender	
Table 16: Individuals by Age Group	
Table 17: Year to Date, by Gender & Age Group	
Combined	12
Table 18: Individuals in NSP, by Gender	
Table 19: Individuals in NSP, by Gender: Steroid Users omitted	
Table 20: Individuals in NSP, by Age Group	
Table 21: Individuals in NSP, by Age Group: Steroid Users omitted	
Table 22: Year to Date, by Gender & Age Group	
Table 23: Total Syringes Provided	

National Drug Treatment Monitoring System (NDTMS) 14

Table 24: Individuals in contact with Treatment Services, by Gender

Table 25: Year to Date, by Gender

Table 26: Individuals in contact with Treatment Services, by Age Group

Table 27: Year to Date, by Age Group

Table 28: Ethnicity of Individuals in Contact with Treatment Services

Table 29: Individuals in contact with Treatment Services, by Main Drug of Use

Young Addaction Outreach 17

Table 30: Individuals by Gender

Table 31: Year to Date, by Gender

Table 32: Main Drug by Age Group

Table 33: Individuals Accommodation

Table 34: Referrals and Interventions

Table 35: Harm reduction Advice and Intervention

Connexions 19

Table 36: Individuals in Contact with Connexions, by Gender

Table 37: Year to Date, by Gender

Table 38: Individuals in Contact with Connexions, by Age

Table 39: Year to Date, by Age

Table 40: Individuals in Contact with Connexions by Drug/Alcohol Problem

Table 41: Year to Date, by Drug/Alcohol Problem

Armistead Pump 21

Table 42: Individuals by Gender

Table 43: Individuals by Age Group

Combined Datasets 22

Table 44: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Table 45: Year to Date, by Gender & Age Group

Cross Matched Datasets 23

Fig 1: Crossover between Agency NSP and NDTMS datasets

Fig 2: Crossover between Pharmacy NSP and NDTMS datasets

Fig 3: Crossover between YTD Agency NSP and NDTMS datasets

Fig 4: Crossover between YTD Pharmacy NSP and NDTMS datasets

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.


To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle and syringe programmes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.



The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)

Quarter 4 (2009/10)

Introduction

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	334	82.3
Female	72	17.7
Age Group		
Under 18	0	0.0
18-19	25	6.2
20-24	91	22.4
25-29	76	18.7
30-34	59	14.5
35-39	67	16.5
40-44	41	10.1
45+	47	11.6
Total	406	100

Table 2: Year to Date, by Gender & Age Group

	Gender				<i>Total in Age Group</i>	
	Male		Female			
Age Group	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	102	7.3	13	4.4	115	6.8
20-24	288	20.5	43	14.4	331	19.5
25-29	270	19.2	42	14.1	312	18.3
30-34	219	15.6	61	20.5	280	16.5
35-39	226	16.1	74	24.8	300	17.6
40-44	166	11.8	30	10.1	196	11.5
45+	132	9.4	35	11.7	167	9.8
Total	1,403	100	298	100	1,701	100

Table 3: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly	Monthly
Amphetamines	-	-	-
Benzodiazepines	-	-	-
Cannabis	32	11	1
Crack	3	4	0
Cocaine	7	40	94
Ecstasy	-	-	-
Heroin	109	46	11
Methadone	3	0	0
Other	-	-	-

40 individuals did not report their main drug of use

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where “Main drug” is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the “Main Drug”. However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

NEEDLE AND SYRINGE PROGRAMMES

Quarter 4 (2009/10)

Introduction

Data are collected directly from NSP providers. Analysis of NSP data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

Please note that the closure of the Lighthouse Project (LHP) resulted in a severe, but temporary, disruption to the agency-based needle and syringe programme service. Consequently there is a short period within Quarter 2 (2009/10) for which we have no data this is reflected in the year to date figures supplied for this quarter. All sites have since reopened and are supplying monitoring data however the year to date figures may appear lower comparable to Q4 (2008/09) due to LHP closure. Please contact us if you require further information.

AGENCY NSP

Table 4: Individuals by Gender

New Clients	n	%
Male	36	97.3
Female	1	2.7
<i>Total</i>	37	100
All Clients		
Male	179	96.2
Female	7	3.8
<i>Total</i>	186	100

Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	9	90.0
Female	1	10.0
<i>Total</i>	10	100
All Clients		
Male	62	89.9
Female	7	10.1
<i>Total</i>	69	100

Table 6: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	1	2.7	2	1.1
18-19	0	0.0	1	<1
20-24	6	16.2	18	9.7
25-29	9	24.3	38	20.4
30-34	9	24.3	38	20.4
35-39	4	10.8	36	19.4
40-44	5	13.5	26	14.0
45+	3	8.1	27	14.5
Total	37	100	186	100

Table 7: Individuals by Age Group: Steroid Users omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	1	10.0	1	1.4
18-19	0	0.0	0	0.0
20-24	0	0.0	2	2.9
25-29	0	0.0	6	8.7
30-34	3	30.0	11	15.9
35-39	2	20.0	14	20.3
40-44	3	30.0	15	21.7
45+	1	10.0	20	29.0
Total	10	100	69	100

Table 8: Gender by Age Group of Individuals

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	2	1.1	0	0.0
18-19	1	<1	0	0.0
20-24	17	9.5	1	14.3
25-29	37	20.7	1	14.3
30-34	37	20.7	1	14.3
35-39	34	19.0	2	28.6
40-44	25	14.0	1	14.3
45+	26	14.5	1	14.3
Total	179	100	7	100

Table 9: Gender by Age Group: Steroid Users omitted

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	1	1.6	0	0.0
18-19	0	0.0	0	0.0
20-24	1	1.6	1	14.3
25-29	5	8.1	1	14.3
30-34	10	16.1	1	14.3
35-39	12	19.4	2	28.6
40-44	14	22.6	1	14.3
45+	19	30.6	1	14.3
Total	62	100	7	100

Table 10: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	4	<1	0	0.0	4	<1
18-19	9	1.5	0	0.0	9	1.4
20-24	76	12.3	5	13.9	81	12.3
25-29	146	23.5	4	11.1	150	22.9
30-34	124	20.0	10	27.8	134	20.4
35-39	106	17.1	7	19.4	113	17.2
40-44	91	14.7	3	8.3	94	14.3
45+	64	10.3	7	19.4	71	10.8
Total	620	100	36	100	656	100

Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	2	1.0	0	0.0	2	<1
18-19	2	1.0	0	0.0	2	<1
20-24	6	3.0	5	15.6	11	4.8
25-29	15	7.6	4	12.5	19	8.3
30-34	35	17.7	8	25.0	43	18.7
35-39	47	23.7	6	18.8	53	23.0
40-44	53	26.8	3	9.4	56	24.3
45+	38	19.2	6	18.8	44	19.1
Total	198	100	32	100	230	100

Table 12: Main Drug of Use for New Agency NSP Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	8	22.2	10	100.0
Methadone	0	0.0	0	0.0
Steroids	27	75.0	0	0.0
Various	1	2.8	0	0.0
Unknown	0	0.0	0	0.0
Total*	36	100	1	100

Table 13: Main Drug of Use for All Agency NSP Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	54	30.2	6	85.7
Methadone	3	1.7	0	0.0
Steroids	117	65.4	0	0.0
Various	1	<1	0	0.0
Unknown	4	2.2	1	14.3
Total	179	100	7	100

Current Quarter; Melanotan Clients

- 0 New Male clients reported using melanotan during Q4
- 0 New Female clients reported using melanotan during Q4
- 0 Male clients reported using melanotan during Q4
- 2 Female clients reported using melanotan during Q4

Table 14: Main Drug of Use for New Agency NSP Clients, by Age Group

Age Group	Ampheta- mine		Benzodi- azepine		Cocaine		Crack		Heroin		Methadone		Steroids	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Under 18	-	-	-	-	-	-	-	-	0	0.0	-	-	0	0.0
18-19	-	-	-	-	-	-	-	-	0	0.0	-	-	0	0.0
20-24	-	-	-	-	-	-	-	-	0	0.0	-	-	6	22.2
25-29	-	-	-	-	-	-	-	-	0	0.0	-	-	9	33.3
30-34	-	-	-	-	-	-	-	-	3	33.3	-	-	6	22.2
35-39	-	-	-	-	-	-	-	-	2	22.2	-	-	2	7.4
40-44	-	-	-	-	-	-	-	-	3	33.3	-	-	2	7.4
45+	-	-	-	-	-	-	-	-	1	11.1	-	-	2	7.4
Total	-	-	-	-	-	-	-	-	9	100	-	-	27	100

% Totals are by Drug, not Age Group.

Please Note: Due to a change in reporting methods main drug of use by age group will only be reported for new clients. Information on age group for all clients is available on request.

PHARMACY NSP

Table 15: Individuals by Gender

New Clients	n	%
Male	859	86.2
Female	137	13.8
<i>Total</i>	996	100
All Clients		
Male	1624	84.8
Female	290	15.2
<i>Total</i>	1,914	100

Table 16: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	5	<1	5	<1
18-19	18	1.8	23	1.2
20-24	114	11.4	189	9.9
25-29	169	17.0	302	15.8
30-34	172	17.3	307	16.0
35-39	200	20.1	415	21.7
40-44	183	18.4	396	20.7
45+	135	13.6	277	14.5
<i>Total</i>	996	100	1,914	100

Table 17: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	13	<1	0	0.0	13	<1
18-19	74	1.6	17	1.9	91	1.7
20-24	539	11.8	59	6.7	598	10.9
25-29	766	16.7	116	13.1	882	16.1
30-34	756	16.5	134	15.1	890	16.3
35-39	1002	21.9	230	25.9	1,232	22.5
40-44	864	18.9	155	17.5	1,019	18.6
45+	569	12.4	176	19.8	745	13.6
<i>Total</i>	4,583	100	887	100	5,470	100

COMBINED PHARMACY AND AGENCY NSP

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 18: Individuals in NSP, by Gender

New Clients	n	%
Male	892	86.7
Female	137	13.3
<i>Total</i>	1,029	100
All Clients		
Male	1,781	85.8
Female	294	14.2
Total	2,075	100

Table 19: Individuals in NSP, by Gender: Steroid Users Omitted*

New Clients	n	%
Male	865	86.3
Female	137	13.7
<i>Total</i>	1,002	100
All Clients		
Male	1,665	85.0
Female	294	15.0
Total	1,959	100

*Only known steroid users, based on Agency NSP data, have been omitted.

Table 20: Individuals in NSP, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	6	<1	7	<1
18-19	18	1.7	24	1.2
20-24	120	11.7	204	9.8
25-29	177	17.2	336	16.2
30-34	180	17.5	342	16.5
35-39	204	19.8	446	21.5
40-44	187	18.2	418	20.1
45+	137	13.3	298	14.4
Total	1,029	100	2,075	100

Table 21: Individuals in NSP by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	6	<1	6	<1
18-19	18	1.8	23	1.2
20-24	114	11.4	188	9.6
25-29	168	16.8	304	15.5
30-34	174	17.4	315	16.1
35-39	202	20.2	425	21.7
40-44	185	18.5	407	20.8
45+	135	13.5	291	14.9
Total	1,002	100	1,959	100

Table 22: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	17	<1	0	0.0	17	<1
18-19	82	1.6	17	1.9	99	1.7
20-24	597	11.8	58	6.4	655	11.0
25-29	887	17.5	118	13.0	1,005	16.8
30-34	861	17.0	143	15.8	1,004	16.8
35-39	1,069	21.1	232	25.6	1,301	21.8
40-44	937	18.5	160	17.6	1,097	18.3
45+	624	12.3	179	19.7	803	13.4
Total	5,074	100	907	100	5,981	100

Table 23: Total Syringes Provided

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	13,047	123,094	136,141	498,609

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

National Drug Treatment Monitoring System (NDTMS)

Quarter 4 (2009/10)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

Table 24: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	643	76.8
Female	194	23.2
<i>Total</i>	837	100
All Clients		
Male	4,018	72.6
Female	1,519	27.4
<i>Total</i>	5,537	100

Table 25: Year to Date, by Gender

New Clients	n	%
Male	2,116	75.5
Female	686	24.5
<i>Total</i>	2,802	100
All Clients		
Male	4,152	72.5
Female	1,572	27.5
<i>Total</i>	5,724	100

Table 26: Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	49	5.9	343	6.2
18-19	38	4.5	142	2.6
20-24	111	13.3	453	8.2
25-29	110	13.1	569	10.3
30-34	120	14.3	906	16.4
35-39	181	21.6	1,324	23.9
40-44	138	16.5	1,043	18.8
45+	90	10.8	757	13.7
Total	837	100	5,537	100

Table 27: Year to Date, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	207	7.4	357	6.2
18-19	97	3.5	146	2.6
20-24	291	10.4	485	8.5
25-29	336	12.0	592	10.3
30-34	423	15.1	948	16.6
35-39	592	21.1	1,382	24.1
40-44	495	17.7	1,047	18.3
45+	361	12.9	767	13.4
Total	2,802	100	5,724	100

Table 28: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	773	92.4	5,059	91.4
White Irish	7	<1	36	<1
Other White	3	<1	21	<1
White & Black Caribbean	6	<1	27	<1
White & Black African	1	<1	14	<1
African	2	<1	7	<1
White & Asian	1	<1	12	<1
Other Asian	4	<1	15	<1
Other Mixed	2	<1	32	<1
Other Black	12	1.4	54	1.0
Caribbean	1	<1	6	<1
Chinese	1	<1	9	<1
Other	3	<1	21	<1
Unknown	21	2.5	224	4.0
Total	837	100	5,537	100

Table 29: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	404	48.3	3,211	58.0
Methadone	39	4.7	331	6.0
Other Opiates	14	1.7	63	1.1
Benzodiazepine	3	<1	20	<1
Amphetamines	8	1.0	45	<1
Cocaine	189	22.6	903	16.3
Crack	23	2.7	160	2.9
Hallucinogens	0	0.0	7	<1
Ecstasy	0	0.0	7	<1
Cannabis	154	18.4	749	13.5
Prescription Drugs	0	0.0	13	<1
Antidepressants	1	<1	5	<1
Other/Unknown	2	<1	23	<1
Total	837	100	5,537	100

YOUNG ADDACTION OUTREACH

Quarter 4 (2009/10)

Background

Young Addaction provide a confidential support service for young people with substance use issues, advice and guidance are provided along with harm reduction education. Data provided by Young Addaction in Liverpool are shown here.

Table 30: Individuals by Gender

Gender	n	%
Male	12	40.0
Female	18	60.0
Total	30	100

Table 31: Year to Date, by Gender

Gender	n	%
Male	63	59.4
Female	43	40.6
Total	106	100

Table 32: Main Drug by Age Group

Age Group	Alcohol		Cannabis		Cocaine		Heroin	
	n	%	n	%	n	%	n	%
Under 18	11	100	8	72.7	0	0.0	3	100
18-19	0	0.0	2	18.2	0	0.0	0	0.0
20-24	0	0.0	1	9.1	0	0.0	0	0.0
Total	11	100	11	100	0	0.0	3	100

Table 33: Individuals Accommodation

Accommodation Type	n	%
Hostel	2	6.7
NFA	2	6.7
Parental Home	23	76.7
Housing Association	0	0.0
Owner Occupied	0	0.0
Supported Housing	3	10.0
Unknown	0	0.0
Total	30	100

Table 34: Referrals and Interventions

Referral/Intervention Type	n	%
Healthcare Services	1	3.3
Treatment Service	1	3.3
Other Professional	1	3.3
Healthy Schools	1	3.3
Social Services	1	3.3
Substance Misuse Education	9	30.0
Motivational work	10	33.3
Accompany to Appointments	1	3.3
Complimentary Therapy	1	3.3
Mental Health Services	1	3.3
Other Organisation	1	3.3
OKUK	2	6.6
Total	30	100

Table 35: Harm Reduction Advice & Information

Harm Reduction Advice Type	n	%
Sexual Risk	4	7.8
Drug Information	5	9.8
Physical/Mental Health	1	2.0
Diet Nutrition	1	2.0
Change Sexual Behaviour	2	3.9
Drug Advice	9	17.6
Addaction Details	4	7.8
Safer Drinking	8	15.7
Sharing Equipment	1	2.0
Outreach Services	5	9.8
Gave Food	2	3.9
Gave Drink	3	5.9
Sexual Health	1	2.0
Other Harm Reduction	5	9.8
Total	51	100

CONNEXIONS
Quarter 4 (2009/10)

Background

Connexions provide a support service for young people, aged 13-19. The Greater Merseyside Connexions Partnership provides data presented here.

Table 36: Individuals in Contact with Connexions, by Gender

Gender	n	%
Male	65	58.0
Female	47	42.0
Total	112	100

Table 37: Year to Date, by Gender

Gender	n	%
Male	106	60.9
Female	68	39.1
Total	174	100

Table 38: Individuals in Contact with Connexions, by Age

Age Group	n	%
16	16	14.3
17	30	26.8
18	40	35.7
19	26	23.2
Total	112	100

Table 39: Year to Date, by Age

Age Group	n	%
16	25	14.4
17	40	23.0
18	65	37.4
19	44	25.3
Total	174	100

Table 40: Individuals in Contact with Connexions by Drug/Alcohol Problem

Substance	n	%
Alcohol/Other*	27	24.1
Drugs	85	75.9
Total	112	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

Table 41: Year to Date, by Drug/Alcohol problem

Substance	n	%
Alcohol/Other*	49	28.2
Drugs	125	71.8
Total	174	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

ARMISTEAD PUMP

Quarter 4 (2009/10)

Background

Armistead Pump provide a confidential needle and syringe programme for steroid users provided at a weekly drop in service in Liverpool City Centre at the Armistead Centre. Sexual health promotion is included alongside referral for blood borne virus testing, hepatitis B vaccination and sexual health screening. Literature relating to safer steroid use is available as well as the opportunity to discuss safer injecting practice. This is a new service which opened in February 2010 and data provided by Armistead Pump are shown here.

Table 42: Individuals by Gender

New Clients	n	%
Male	12	100
Female	0	0.0
<i>Total</i>	12	100
All Clients		
Male	12	100
Female	0	0.0
<i>Total</i>	12	100

Table 43: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	1	8.3	1	8.3
18-19	0	0.0	0	0.0
20-24	2	16.7	2	16.7
25-29	3	25.0	3	25.0
30-34	2	16.7	2	16.7
35-39	1	8.3	1	8.3
40-44	2	16.7	2	16.7
45+	1	8.3	1	8.3
<i>Total</i>	12	100	12	100

Please Note: All clients are shown as new clients as Armistead Pump is a new service opened during Q4 2009-10. As a result there are no year to date figures available during this reporting period.

COMBINED DATASETS

Quarter 4 (2009/10)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, NSP (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 44: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%
Male	5,703	75.7
Female	1,827	24.3
Age Group		
Under 18	411	5.5
18-19	232	3.1
20-24	692	9.2
25-29	905	12.0
30-34	1,225	16.3
35-39	1,683	22.4
40-44	1,382	18.4
45+	1,000	13.3
Total	7,530	100

Table 45: Year to Date, by Gender and Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	383	4.0	117	4.5	500	4.1
18-19	350	3.6	90	3.5	440	3.6
20-24	1,149	11.9	209	8.1	1,358	11.1
25-29	1,424	14.8	306	11.9	1,730	14.2
30-34	1,557	16.2	444	17.3	2,001	16.4
35-39	1,963	20.4	640	24.9	2,603	21.3
40-44	1,652	17.2	410	15.9	2,062	16.9
45+	1,154	12.0	356	13.8	1,510	12.4
Total	9,632	100	2,572	100	12,204	100

CROSS-MATCHED DATASETS

Quarter 4 (2009/10)

Data are shown for the crossover between each type of NSP and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of NSP site.

Fig 1: Crossover between Agency NSP and NDTMS datasets




Fig 2: Crossover between Pharmacy NSP and NDTMS datasets




Fig 3: Year to Date Crossover between Agency NSP and NDTMS datasets




Fig 4: Year to Date Crossover between Pharmacy NSP and NDTMS datasets

